Nusinersen for the treatment of spinal muscular atrophy

References

• Zerres K, Rudnik-Schoneborn S. Natural history in proximal spinal muscular atrophy. Clinical analysis of 445 patients and suggestions for a modification of existing classifications. Arch Neurol. 1995;52:518–523.
   PubMed Web of Science ®Google Scholar
• Sugarman EA, Nagan N, Zhu H, et al. Pan-ethnic carrier screening and prenatal diagnosis for spinal muscular atrophy: clinical laboratory analysis of >72,400 specimens. Ejhg. 2012;20:27–32.
   PubMed Web of Science ®Google Scholar
• Oskoui M, Levy G, Garland CJ, et al. The changing natural history of spinal muscular atrophy type 1. Neurology. 2007;69:1931–1936.
   PubMed Web of Science ®Google Scholar
• Finkel RS, McDermott MP, Kaufmann P, et al. Observational study of spinal muscular atrophy type I and implications for clinical trials. Neurology. 2014;83:810–817.
   PubMed Web of Science ®Google Scholar
• Kolb S NeuroNEXT SMA Biomarker Study. Presented at Cure SMA 2016 Meeting; 2016 June 19; Anaheim, CA
   Google Scholar
• Kaufmann P, McDermott MP, Darras BT, et al. Observational study of spinal muscular atrophy type 2 and 3: functional outcomes over 1 year. Arch Neurol. 2011;68:779–786.
   PubMedGoogle Scholar
• Kaufmann P, McDermott MP, Darras BT, et al. Prospective cohort study of spinal muscular atrophy types 2 and 3. Neurology. 2012;79:1889–1897.
   PubMed Web of Science ®Google Scholar
• Kolb SK, Coffey CS, Yankey JW, et al. Baseline results of the NeuroNEXT spinal muscular atrophy infant biomarker study. Ann Clin Translational Neurol. 2016;3:132–145.
   PubMed Web of Science ®Google Scholar
• Glanzman AM, McDermott MP, Montes J, et al. Validation of the Children’s Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND). Pediatr Phys Ther. 2011;23:322–326.
   PubMed Web of Science ®Google Scholar
• Haataja L, Mercuri E, Regev R, et al. Optimality score for the neurologic examination of the infant at 12 and 18 months of age. J Pediatrics. 1999;135:153–161.
   PubMed Web of Science ®Google Scholar
• Kuntz N, Farwell W, Zhong ZJ, et al. Nusinersen in Infants Diagnosed with Spinal Muscular Atrophy (SMA): study design and initial interim efficacy and safety findings from the phase 3 international ENDEAR study (CCI.002). Neurology. 2017 April 18;88(16 Supplement CCI.002):1526–632X. April 24, 2017 - Plenary Session - Contemporary Clinical Issues |.
   Google Scholar
• Glanzman AM, O’Hagen JM, McDermott MP, et al. Validation of the Expanded Hammersmith Functional Motor Scale in spinal muscular atrophy type II and III. J Child Neurol. 2011;26:1499–1507.
   PubMed Web of Science ®Google Scholar
• Dunaway Young S, Montes J, Kramer SS, et al. Six-minute walk test is reliable and valid in spinal muscular atrophy. Muscle Nerve. 2016;54:836–842.
   PubMed Web of Science ®Google Scholar
• Mazzone ES, Mayhew A, Montes J, et al. Revised upper limb module for spinal muscular atrophy: development of a new module. Muscle Nerve. 2017;55:869–874.
   PubMed Web of Science ®Google Scholar
• Swoboda KJ, Prior TW, Scott CB, et al. Natural history of denervation in SMA: relation to age, SMN2 copy number, and function. Ann Neurol. 2005;57:704–712.
   PubMed Web of Science ®Google Scholar
• Burghes AH, Beattie CE, Burghes AHM, et al. Spinal muscular atrophy: why do low levels of survival motor neuron protein make motor neurons sick? Nat Rev Neurosci. 2009;10:597–609.
   PubMed Web of Science ®Google Scholar
• Pellizzoni L, Yong J, Dreyfuss G. Essential role for the SMN complex in the specificity of snRNP assembly. Science. 2002;298:1775–1779.
   PubMed Web of Science ®Google Scholar
• Singh RN, Howell MD, Ottesen EW, et al. Diverse role of survival motor neuron protein. Biochim Biophys Acta. 2017;1860:299–315.
   PubMed Web of Science ®Google Scholar
• Harding BN, Kariya S, Monani U, et al. Spectrum of neuropathophysiology in spinal muscular atrophy type I. J Neuropathol Exp Neurol. 2015;74:15–24.
   PubMed Web of Science ®Google Scholar
• McGovern VL, Iyer CC, Arnold WD, et al. SMN expression is required in motor neurons to rescue electrophysiological deficits in the SMNΔ7 mouse model of SMA. Hum Mol Genet. 2015;24:5524–5541.
   PubMed Web of Science ®Google Scholar
• Mentis GZ, Blivis D, Liu W, et al. Early functional impairment of sensory-motor connectivity in a mouse model of spinal muscular atrophy. Neuron. 2011;69:453–467.
   PubMed Web of Science ®Google Scholar
• Imlach W, McCabe BD. Electrophysiological methods for recording synaptic potentials from the NMJ of drosophila larvae. JoVE. 2009 February 6(24):ed2009.
   Google Scholar
• Imlach WL, Beck ES, Choi BJ, et al. SMN is required for sensory-motor circuit function in drosophila. Cell. 2012;151:427–439.
   PubMed Web of Science ®Google Scholar
• Lorson CL, Hahnen E, Androphy EJ, et al. A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy. Proc Natl Acad Sci U S A. 1999;96:6307–6311.
   PubMed Web of Science ®Google Scholar
• Monani UR, Lorson CL, Parsons DW, et al. A single nucleotide difference that alters splicing patterns distinguishes the SMA gene SMN1 from the copy gene SMN2. Hum Mol Genet. 1999;8:1177–1183.
   PubMed Web of Science ®Google Scholar
• Mailman MD, Heinz JW, Papp AC, et al. Molecular analysis of spinal muscular atrophy and modification of the phenotype by SMN2. Genet Med. 2002;4:20–26.
   PubMed Web of Science ®Google Scholar
• Wirth B, Herz M, Wetter A, et al. Quantitative analysis of survival motor neuron copies: identification of subtle SMN1 mutations in patients with spinal muscular atrophy, genotype-phenotype correlation, and implications for genetic counseling. Am J Hum Genet. 1999;64:1340–1356.
   PubMed Web of Science ®Google Scholar
• Farrar MA, Park SB, Vucic S, et al. Emerging therapies and challenges in spinal muscular atrophy. Ann Neurol. 2017;81:355–368.
   PubMed Web of Science ®Google Scholar
• Crawford TO, Paushkin SV, Kobayashi DT, et al. Evaluation of SMN protein, transcript, and copy number in the biomarkers for spinal muscular atrophy (BforSMA) clinical study. PLoS One. 2012;7:e33572.
   PubMed Web of Science ®Google Scholar
• Meyer K, Ferraiuolo L, Schmelzer L, et al. Improving single injection CSF delivery of AAV9-mediated gene therapy for SMA: a dose-response study in mice and nonhuman primates. Mol Ther. 2015;23:477–487.
   PubMed Web of Science ®Google Scholar
• Naryshkin NA, Weetall M, Dakka A, et al. Motor neuron disease. SMN2 splicing modifiers improve motor function and longevity in mice with spinal muscular atrophy. Science. 2014;345:688–693.
   PubMed Web of Science ®Google Scholar
• Bertini E, Dessaud E, Mercuri E, et al. Safety and efficacy of olesoxime in patients with type 2 or non-ambulatory type 3 spinal muscular atrophy: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol. 2017;16:513–522.
   PubMed Web of Science ®Google Scholar
• Russell AJ, Hartman JJ, Hinken AC, et al. Activation of fast skeletal muscle troponin as a potential therapeutic approach for treating neuromuscular diseases. Nat Med. 2012;18:452–455.
   PubMed Web of Science ®Google Scholar
• Havens MA, Hastings ML. Splice-switching antisense oligonucleotides as therapeutic drugs. Nucleic Acids Res. 2016;44:6549–6563.
   PubMed Web of Science ®Google Scholar
• Singh NK, Singh NN, Androphy EJ, et al. Splicing of a critical exon of human Survival Motor Neuron is regulated by a unique silencer element located in the last intron. Mol Cell Biol. 2006;26:1333–1346.
   PubMed Web of Science ®Google Scholar
• Hua Y, Vickers TA, Okunola H, et al. Antisense masking of an hnRNP A1/A2 intronic splicing silencer corrects SMN2 splicing in transgenic mice. Am J Hum Genet. 2008;82:834–848.
   PubMed Web of Science ®Google Scholar
• Passini MA, Bu J, Richards AM, et al. Antisense oligonucleotides delivered to the mouse CNS ameliorate symptoms of severe spinal muscular atrophy. Sci Transl Med. 2011;3:72ra18.
   PubMed Web of Science ®Google Scholar
• Finkel RS, Chiriboga CA, Vajsar J, et al. Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study. Lancet. 2016;388:3017–3026.
   PubMed Web of Science ®Google Scholar
• Chiriboga CA, Swoboda KJ, Darras BT, et al. Results from a phase 1 study of nusinersen (ISIS-SMN(Rx)) in children with spinal muscular atrophy. Neurology. 2016;86:890–897.
   PubMed Web of Science ®Google Scholar
• FDA. U.S. Department of Health and Human Services. Center for drug evaluation and research. Application number: 209531Orig1s000. Medical Reviews. [online]. [cited 2017 Feb 2]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/209531Orig1s000MedR.pdf
   Google Scholar
• Chiriboga CA, Darras B, Montes J, et al. Nusinersen in treatment-naïve children with later-onset spinal muscular atrophy (SMA): efficacy results from a phase 1b/2a multicentre study (CS2) and its open-label extension (CS12). 2017 CureSMA Abstract (Meeting); June 29–July 2, 2017, Orlando, FL, USA
   Google Scholar
• De Vivo D, Hwu W, Reyna S, et al. Interim efficacy and safety results from the phase 2 NURTURE study evaluating nusinersen in presymptomatic infants with spinal muscular atrophy.69th American Academy of Neurology Meeting. 2017 (Abstract S46.003) April 22-27, Boston, MA, USA.
   Google Scholar
• Keidan I, Bielorei B, Berkenstadt H, et al. Prospective evaluation of clinical and laboratory effects of intrathecal chemotherapy on children with acute leukemia. J Pediatr Hematol Oncol. 2005;27:307–310.
   PubMed Web of Science ®Google Scholar
• Spinraza. TM (nusinersen) injection, 12 mg/5ml Prescribing information [serial online]. [cited 2017 May 15]. Available from: https://www.spinraza.com/content/dam/commercial/specialty/spinraza/caregiver/en%20_us/pdf/spinraza-prescribing-information.pdf
   Google Scholar
• Prior TW, Krainer AR, Hua Y, et al. A positive modifier of spinal muscular atrophy in the SMN2 gene. Am J Hum Genet. 2009;85:408–413.
   PubMed Web of Science ®Google Scholar
• Lutz CM, Kariya S, Patruni S, et al. Postsymptomatic restoration of SMN rescues the disease phenotype in a mouse model of severe spinal muscular atrophy. J Clin Invest. 2011;121:3029–3041.
   PubMed Web of Science ®Google Scholar